2021
Socioeconomic Determinants of the Use of Molecular Testing in Stage IV Colorectal Cancer
Punekar S, Griffin M, Masri L, Roman S, Makarov D, Sherman S, Becker D. Socioeconomic Determinants of the Use of Molecular Testing in Stage IV Colorectal Cancer. American Journal Of Clinical Oncology 2021, 44: 597-602. PMID: 34753883, DOI: 10.1097/coc.0000000000000875.Peer-Reviewed Original ResearchConceptsStage IV colorectal cancerKRAS testingColorectal cancerMedicaid insuranceMultivariable-adjusted Cox proportional hazards modelsStage IV colorectal adenocarcinomaEpidermal growth factor receptor monoclonal antibodiesCox proportional hazards modelMultivariable logistic regression modelAdvanced colorectal cancerEnd Results (SEER) databaseRisk of deathReceptor monoclonal antibodyProportional hazards modelWild-type KRASSocioeconomic disparities persistLogistic regression modelsCRC patientsResults databaseColorectal adenocarcinomaKRAS mutationsHigher median household incomeHazards modelPatientsMolecular testingRole of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer
Punekar S, Castillo R, Sandigursky S, Cho D. Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer. Journal Of Immunotherapy 2021, 44: 335-337. PMID: 34166301, DOI: 10.1097/cji.0000000000000380.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsAutoimmune conditionsDiscontinuation of ICIsPD-1/PD-L1Concurrent immune checkpoint inhibitorsImmune-related adverse eventsMetastatic renal cell carcinomaRole of IVIgUnderlying autoimmune conditionClasses of medicationsRenal cell carcinomaParaneoplastic dermatomyositisIntravenous immunoglobulinAdverse eventsPD-L1Antitumor responseCell carcinomaImmunomodulatory agentsMetastatic cancerImmune pathwaysExacerbationPatientsTreatmentCancerResponse to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma
Shah P, Punekar S, Pavlick A. Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma. Melanoma Research 2021, 31: 242-248. PMID: 33741813, DOI: 10.1097/cmr.0000000000000730.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overFemaleHumansImmune Checkpoint InhibitorsMaleMelanomaMiddle AgedNeoplasm GradingConceptsImmune-related adverse eventsProgression-free survivalHigh-grade immune-related adverse eventsImmune checkpoint inhibitorsOverall survivalDisease progressionAdverse eventsAdvanced melanomaInitial irAEImmune checkpoint inhibitor rechallengeImmune related adverse eventsMedian progression-free survivalUnresectable stage III melanomaMedian overall survivalPercent of patientsRelated adverse eventsStage III melanomaLimited clinical evidenceRisk-benefit profileContinuation of treatmentNYU Langone HealthICI initiationICI rechallengeICI therapyCheckpoint inhibitors
2020
Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database
Punekar S, Kaakour D, Masri-Lavine L, Hajdu C, Newman E, Becker D. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database. American Journal Of Clinical Oncology 2020, 43: 846-849. PMID: 32910023, DOI: 10.1097/coc.0000000000000761.Peer-Reviewed Original ResearchConceptsG3 neuroendocrine tumorsColorectal neuroendocrine tumorsNeuroendocrine tumorsOverall survivalUnmarried patientsCox proportional hazards modelEnd Results (SEER) databaseGastrointestinal neuroendocrine tumorsPredictors of survivalPrognosis of patientsNational registry studyProportional hazards modelOlder patientsRegistry studySEER databaseWorse survivalMedian ageSurveillance EpidemiologyBlack patientsResults databaseTumor characteristicsHazards modelPatientsSmall studyLogistic regression
2019
Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
BECKER D, IYENGAR A, PUNEKAR S, NG J, ZAMAN A, LOEB S, BECKER K, MAKAROV D. Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. Anticancer Research 2019, 39: 2467-2473. PMID: 31092441, DOI: 10.21873/anticanres.13366.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAbi/enzaCastration-resistant prostate cancerPSA progressionEnd of lifeProstate cancerVeterans AffairsOlder patientsBlack patientsClinical benefitClinical endpointsHospice servicesNational guidelinesPatientsEnza treatmentAdditional studiesProgressionENZAAbirateroneRegression analysisCancerTreatmentABIEnzalutamideEndpoint
2012
Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma
Friedberg J, Culligan M, Mick R, Stevenson J, Hahn S, Sterman D, Punekar S, Glatstein E, Cengel K. Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma. The Annals Of Thoracic Surgery 2012, 93: 1658-1667. PMID: 22541196, PMCID: PMC4394024, DOI: 10.1016/j.athoracsur.2012.02.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansImmunohistochemistryIntraoperative CareMaleMesotheliomaMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPhotochemotherapyPleuraPleural NeoplasmsRisk AssessmentSurvival AnalysisTime FactorsTreatment OutcomeConceptsProgression-free survivalMacroscopic complete resectionRadical pleurectomyIntraoperative photodynamic therapyNonepithelial subtypeMedian survivalComplete resectionEpithelial subtypesStage III/IV diseaseMedian progression-free survivalStage III/IV cancerPhotodynamic therapyLung-sparing approachLung-sparing surgeryMalignant pleural mesotheliomaPostoperative mortalitySystemic therapyPleural mesotheliomaEpithelial diseasePatientsMesotheliomaSubtypesTherapyMonthsSurvival